-
1.
Kahn SE, et al.. Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. Lancet 2014; 383:1068–1083.
-
2.
Andersen ES, et al.. Do we know the true mechanism of action of the DPP-4 inhibitors? Diabetes Obes Metab 2018; 20:34–41.
-
3.
Davies MJ, et al.. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41:2669–2701.
-
4.
Davidson JA. The placement of DPP-4 inhibitors in clinical practice recommendations for the treatment of type 2 diabetes. Endocr Pract 2013; 19:1050–1061.
-
5.
Tkac I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care 2017; 40:284–286.
-
6.
Lee SG, et al.. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol 2019; 155:172–177.
-
7.
Deacon CF, Lebovitz HE. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab 2016; 18:333–347.
-
8.
Rosenstock J, et al.. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: A randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 2015; 38:376–383.
-
9.
Cooper ME, et al.. Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis 2015; 66:441–449.
-
10.
Groop PH, et al.. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: The randomized MARLINA-T2D trial. Diabetes Obes Metab 2017; 19:1610–1619.
-
11.
Rosenstock J, et al.. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial. JAMA 2019; 321:69–79.
-
12.
Marx N, et al.. Design and baseline characteristics of the CARdiovascular Outcome trial of LINAgliptin versus glimepiride in type 2 diabetes (CAROLINA®). Diab Vasc Dis Res 2015; 12:164–174.
Dipeptidyl Peptidase-4 Inhibitors
After a long period of very few drug choices for the management of type 2 diabetes, during the past 15 years a range of new drug classes has been developed (
These agents inhibit the enzyme DPP-4, which acts to degrade glucagon-like peptide-1 (GLP-1), an incretin hormone. GLP-1 triggers glucose-dependent insulin secretion, reduces glucagon release, and delays gastric emptying (
© 2021 American Society of Nephrology | All Rights Reserved
Powered by: PubFactory